MAIA Biotechnology shares surge 12.59% intraday after FDA grants fast track designation for ateganosine in non-small cell lung cancer.

MAIA Biotechnology surged 12.59% intraday as the FDA granted fast-track designation for ateganosine for non-small cell lung cancer, and the company announced progress in the treatment project with 2026 clinical milestones. The company focuses on developing telomere-targeting anticancer drugs like.